Conference Call to be held Tuesday, July 26th at 4:30pm ET
NEW
YORK, July 26, 2022 /PRNewswire/
-- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a
clinical-stage biopharmaceutical company developing regenerative
therapeutics for neurodegenerative disorders, today announced
changes to its Scientific Advisory Board (SAB) in preparation for
Phase 2 data from its Phase 2b
clinical trial of Bryostatin-1 for patients suffering from advanced
and moderately severe Alzheimer's disease (AD). The SAB is
comprised of industry and academic leaders in science and drug
development and will be instrumental in the further development of
the Company's regenerative therapies across AD, Fragile X syndrome,
and multiple sclerosis (MS).
The SAB will be chaired by Dr. George
Perry, who will serve along with Dr. Marwan Sabbagh, Dr. Paul
Coleman, Professor Robert
Howard, and Dr. Zaven Khachaturian.
"We are extremely pleased to have assembled this world class
Scientific Advisory Board. The expertise and experience within this
group will be invaluable as we prepare for Phase 2 data later this
year, as well as the next steps we will take to advance the
development of our regenerative therapies," stated Dr. Alan Tuchman, Chief Executive Officer.
"Each of these distinguished leaders in AD research brings
pioneering expertise in diverse scientific disciplines, including
molecular mechanisms of neurodegeneration and regeneration,
clinical trials of AD therapeutics, and interacting biochemical
pathways of aging, synaptic loss, and neuronal loss," stated Dr.
Daniel Alkon, President and Chief
Scientific Officer.
Scientific Advisory Board members include:
Dr. George Perry, former
Dean of the College of Sciences, Semmes Distinguished University
Chair in Neurobiology, Professor of Biology and Chemistry at the
University of Texas at San Antonio. Dr.
Perry is recognized in the field of Alzheimer's disease research
particularly for his work on oxidative stress. His research is
primarily focused on the mechanisms and pathophysiological
consequences of the cytopathology of Alzheimer disease. Dr.
Perry is the current and founding editor-in-chief for the
Journal of Alzheimer's Disease, an international
multidisciplinary journal that specializes in Alzheimer's
disease.
Dr. Marwan Sabbagh, a
leader in the field of Alzheimer's disease and related
disorders, is professor of Neurology in the Alzheimer's and Memory
Disorders Division at the Barrow Neurological Institute
in Phoenix, Arizona.
Previously, Dr. Sabbagh served as the Director of the Cleveland
Clinic Lou Ruvo Center for Brain Health. Dr. Sabbagh has published
over 400 scientific and medical research articles on Alzheimer's
disease and remains a prominent investigator and key opinion leader
in nationally recognized Alzheimer's prevention and treatment
trials.
Dr. Paul Coleman, several
decades as a Full Professor at the University
of Rochester School of Medicine during which time he was
Director of the University of Rochester
Medical Center Alzheimer's Disease Center and Director of an NIH
Training Program in Neurobiology of Aging. In 2015, he moved his
laboratory to the Neurodegenerative Disease Research Center at the
Bio-design Institute, Arizona State
University. Dr. Coleman's work has focused on
differentiating changes in the brain in Alzheimer's disease from
changes related to normal, non-demented ageing. Most
recently, Dr. Coleman's work has expanded into the realm of
epigenetics. Dr. Coleman has received a number of awards for
his work, including a Leadership and Excellence in Alzheimer's
Disease Award from the National Institutes of Health (one of 12
ever awarded) and a Pioneer Award from the National Alzheimer's
Association.
Professor Robert Howard,
Professor of Old Age Psychiatry at University College London, and
Mental Health Lead of the University College London Hospitals'
Biomedical Research Centre. He and his colleagues
investigate ways in which mental health symptoms in
older people can be treated most effectively and safely
through development of new psychological therapy
approaches, optimizing the use of
existing medications and of novel and repurposed
agents. Their trials have shown the cognitive, functional, and
independent living benefits of continuing dementia drugs until the
late stages of Alzheimer's disease.
Dr. Zaven Khachaturian is the President of the
Campaign to Prevent Alzheimer Disease (PAD2020.org). He is
the former Director, Office of Alzheimer's Disease at
the National Institutes of Health (NIH), which was
responsible for coordinating all Alzheimer's disease related
activities NIH-wide. He also serves as the Associate Director,
Neuroscience & Neuropsychology of Aging Program at the
National Institution on Aging NIA / NIH. He is widely recognized as
the Chief Architect of NIH-funded programs of research on
brain aging and dementia-Alzheimer syndrome.
As a reminder, Synaptogenix will hold a corporate update
conference call this afternoon for investors. The call will
take place at 4:30pm ET and will
be hosted by the Company's Chief Executive Officer, Dr.
Alan Tuchman, and its President and
Chief Scientific Officer, Dr. Daniel
Alkon. Drs. Tuchman and Alkon will also take live Q&A
following their prepared remarks. The U.S. toll free dial-in for
the conference call is (877) 407-8293, and the international
dial-in number is 1-(201) 689-8349.
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies for
neurodegenerative diseases. Synaptogenix has conducted clinical and
preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in Alzheimer's disease. Preclinical studies have also
demonstrated Bryostatin's regenerative mechanisms of action for the
rare disease, Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial
designs.
Additional information about Synaptogenix, Inc. may be found on
its website: www.synaptogen.com .
Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the anticipated initiation of a clinical trial to treat
Multiple Sclerosis with Bryostatin and continued development
of use of Bryostatin-1 for Alzheimer's disease, Fragile X and other
cognitive diseases. Such forward-looking statements are subject to
risks and uncertainties and other influences, many of which the
Company has no control over. There can be no assurance that the
clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy, that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand its business, significant
government regulation of pharmaceuticals and the healthcare
industry, lack of product diversification, availability of the
Company's raw materials, existing or increased competition, stock
volatility and illiquidity, and the Company's failure to implement
its business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission. The Company does not
undertake to update these forward-looking statements.
Contact Information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-announces-changes-to-scientific-advisory-board-in-preparation-for-phase-2-data-301593226.html
SOURCE Synaptogenix, Inc.